FDA Panel Votes on Tenapanor for Hyperphosphatemia in CKD
For patients who tolerated and remained on therapy, the average treatment effect on serum phosphorus was about -0.7mg/dL.
Hyperphosphatemia
HYPERPHOSPHATEMIA
New Nordic Renal Diet May Benefit Patients With Moderate CKD
The new Nordic renal diet is a plant-focused meal pattern with reduced phosphorus and protein content and more fiber compared with an average Danish diet.
Real-World Phosphate Binder Use Described
Nearly two-thirds of patients receiving dialysis use phosphate binders intermittently, a study found.
CKD-MBD Marker Changes Vary Across Dialysis Modalities
Use of home dialysis and modalities other than conventional in-center hemodialysis is expected to grow.
Hyperphosphatemia Slightly Reduces Calcimimetics’ Effects
Study findings suggest serum phosphate is a negative modulator of calcium receptor activation.
Potassium Binder May Also Lower Phosphate Levels in CKD
Patiromer may be another therapeutic option for patients with both hyperkalemia and hyperphosphatemia.
RCT Data Needed on Phosphate-Lowering Agents and NDD-CKD Outcomes
Systematic reviews on this topic have largely been focused on patients receiving dialysis.
Phosphate Binder Dissatisfaction May Affect Patient Outcomes
Dissatisfaction with taking phosphate binders may influence medication adherence and ultimately clinical outcomes, according to investigators.
FDA Wants Another Study Before Deciding on Tenapanor Approval
Tenapanor inhibits the sodium/hydrogen exchanger 3 to control serum phosphorus in adults with CKD on dialysis.
Tenapanor Monotherapy May Reduce Phosphorus Levels in Patients on Dialysis
Full results from the OPTIMIZE study, due to be completed in August 2021, are forthcoming.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Hyperphosphatemia
Loading... 
Loading...